3-Methyl-3-azabicyclo<3.1.0>hexan-2,4-dion | 34198-65-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 3-Methyl-3-azabicyclo<3.1.0>hexan-2,4-dion
• 英文别名: 3-methyl-3-aza-bicyclo[3.1.0]hexane-2,4-dione；3-Methyl-3-azabicyclo[3.1.0]hexane-2,4-dione
• CAS: 34198-65-7
• 化学式: C₆H₇NO₂
• 分子量: 125.127
• InChiKey: NZWJFURIIGESDE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.7
• 重原子数：
  9
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  37.4
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  N-甲基马来酰亚胺 以 乙醚 、 乙腈 为溶剂， 反应 1.0h， 生成 N-methylitaconimide 、 3-Methyl-3-azabicyclo<3.1.0>hexan-2,4-dion
  参考文献：
  名称：

  Solid-state photochemistry of crystalline pyrazolines: reliable generation and reactivity control of 1,3-biradicals and their potential for the green chemistry synthesis of substituted cyclopropanes

  摘要：

  为了扩展文献中关于偶氮烷烃固态光脱氮反应的有限实例，我们制备了一系列具有不同4,4-取代基的7-烷基-2,3,7-三氮杂双环[3.3.0]辛-2-烯-6,8-二酮晶体。它们在溶液和固态下的光化学行为取决于1-吡唑啉环的4,4-取代基，未取代的吡唑啉12在溶液和固态下都会产生混合产物。二苯基取代吡唑啉13在溶液中自发脱氮，但在固态下需要光照才能定量反应。叔丁基苯基取代吡唑啉14在溶液和固态下均表现出化学和立体选择性脱氮，以定量产率产生单一产物。

  DOI：

  10.1039/c2pp25263e

文献信息

• NEW PHENYLALANINE DERIVATIVES
  申请人：SUZUKI Nobuyasu

  公开号：US20090048236A1

  公开（公告）日：2009-02-19

  Specific phenylalanine derivatives or pharmaceutically acceptable salts thereof have an antagonistic effect on the α4 integrins and, therefore, are usable as therapeutic agents or preventive agents for diseases in which α4 integrin-depending adhesion process participates in the pathology, such as inflammatory diseases, rheumatoid arthritis, inflammatory bowel diseases, systemic lupus erythematosus, multiple sclerosis, Sjögren's syndrome, asthma, psoriasis, allergy, diabetes, cardiovascular diseases, arterial sclerosis, restenosis, tumor proliferation, tumor metastasis and transplantation rejection.

  特定的苯丙氨酸衍生物或其药学上可接受的盐具有对α4整合素的拮抗作用，因此可用作治疗剂或预防剂，用于α4整合素依赖性黏附过程参与病理的疾病，如炎症性疾病、类风湿性关节炎、炎症性肠病、系统性红斑狼疮、多发性硬化症、干燥综合症、哮喘、银屑病、过敏、糖尿病、心血管疾病、动脉硬化、再狭窄、肿瘤增殖、肿瘤转移和移植排斥。
• Aryloxy-Substituted Benzimidazole Derivatives
  申请人：Hashimoto Noriaki

  公开号：US20080125429A1

  公开（公告）日：2008-05-29

  A glucokinase activator is provided; and a treatment and/or a preventive for diabetes, or a treatment and/or a preventive for diabetes such as retinopathy, nephropathy, neurosis, ischemic cardiopathy, arteriosclerosis, and further a treatment and/or a preventive for obesity are provided. The invention relates to a compound of a formula (I): [wherein R 1 and R 2 represent a hydrogen, etc.; R 3 represents a hydrogen atom, a halogen atom, etc.; R 4 each independently represents a hydrogen atom, a lower alkyl group, etc.; Q represents a carbon atom, a nitrogen atom or a sulfur atom (the sulfur atom may be mono- or di-substituted with an oxo group); R 5 and R 6 each represent a hydrogen atom, a lower alkyl group, etc.; X 1 , X 2 , X 3 and X 4 each independently represent a carbon atom or a nitrogen atom; Z represents an oxygen atom, a sulfur atom or a nitrogen atom; Ar represents an aryl or heteroaryl group optionally mono to tri-substituted with a group selected from the substituent group β; ring A represents a 5- or 6-membered nitrogen-containing heteroaromatic group; m indicates an integer of from 1 to 6; n indicates an integer of from 0 to 3; p indicates an integer of from 0 to 2 (provided that at least two of X 1 to X 4 are carbon atoms); q indicates 0 or 1] or its pharmaceutically-acceptable salt, which has an effect of glucokinase activation and is useful as a treatment for diabetes.

  本发明提供了一种葡萄糖激酶激活剂；以及用于糖尿病的治疗和/或预防，或用于糖尿病如视网膜病变、肾病、神经病、缺血性心脏病、动脉硬化等的治疗和/或预防，以及用于肥胖症的治疗和/或预防。本发明涉及一种化合物的公式(I)：[其中R1和R2分别表示氢等；R3表示氢原子、卤原子等；R4各自独立地表示氢原子、低级烷基等；Q表示碳原子、氮原子或硫原子（硫原子可以是单取代或双取代的氧基）；R5和R6各自表示氢原子、低级烷基等；X1、X2、X3和X4各自独立地表示碳原子或氮原子；Z表示氧原子、硫原子或氮原子；Ar表示芳基或杂环芳基，可选择性地单取代至三取代于β取代基；环A表示一个含氮的5-或6成员杂芳基；m表示1至6的整数；n表示0至3的整数；p表示0至2的整数（前提是X1至X4中至少有两个是碳原子）；q表示0或1]或其药学上可接受的盐，具有葡萄糖激酶激活的作用，并且可用作糖尿病的治疗。
• Herbicidal amides
  申请人：FMC Corporation

  公开号：US11357230B2

  公开（公告）日：2022-06-14

  Disclosed are compounds of Formula 1, including all stereoisomers, N-oxides, and salts thereof wherein W, R1, J, Q1, R7, R8, Y, R9 and are as defined in the disclosure. Also disclosed are compositions containing the compounds of Formula 1 and methods for controlling undesired vegetation comprising contacting the undesired vegetation or its environment with an effective amount of a compound or a composition of the invention.

  公开了式 1 的化合物，包括其所有立体异构体、N-氧化物及其盐类 其中 W、R1、J、Q1、R7、R8、Y、R9 和如本文所定义。 本发明还公开了含有式 1 化合物的组合物，以及控制不良植被的方法，包括将有效量的本发明化合物或组合物与不良植被或其环境接触。
• ARYLOXY-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES
  申请人：MSD K.K.

  公开号：EP1810969B1

  公开（公告）日：2013-08-07
• ORGANIC COMPOUNDS AND THEIR USES
  申请人：NOVARTIS AG

  公开号：US20130149281A1

  公开（公告）日：2013-06-13

  The present application describes a method of treating an HCV-associated disorder by administering to a subject in need thereof a pharmaceutically effective amount of a compound of formula I in combination with an additional HCV-modulating compound.